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Abstract
Multiresistant nosocomial pathogens often cause life-threatening infections that are some-
times untreatable with currently available antibiotics. Staphylococci and enterococci are the
predominant Gram-positive species associated with hospital-acquired infections. These in-
fections often lead to extended hospital stay and excess mortality. In this study, a panel of
fully human monoclonal antibodies was isolated from a healthy individual by selection of B-
cells producing antibodies with high opsonic killing against E. faecalis 12030. Variable do-
mains (VH and VL) of these immunoglobulin genes were amplified by PCR and cloned into
an eukaryotic expression vector containing the constant domains of a human IgG1 mole-
cule and the human lambda constant domain. These constructs were transfected into CHO
cells and culture supernatants were collected and tested by opsonophagocytic assay
against E. faecalis and S. aureus strains (including MRSA). At concentrations of 600 pg/ml,
opsonic killing was between 40% and 70% against all strains tested. Monoclonal antibodies
were also evaluated in a mouse sepsis model (using S. aureus LAC and E. faecium), a
mouse peritonitis model (using S. aureus Newman and LAC) and a rat endocarditis model
(using E. faecalis 12030) and were shown to provide protection in all models at a concentra-
tion of 4 μg/kg per animal. Here we present a method to produce fully human IgG1 monoclo-
nal antibodies that are opsonic in vitro and protective in vivo against several multiresistant
Gram-positive bacteria. The monoclonal antibodies presented in this study are significantly
more effective compared to another monoclonal antibody currently in clinical trials.
Introduction
Infections caused by multiresistant nosocomial pathogens are one of the major problems in
modern medicine. A recent report from the Centers for Disease Control and Prevention
(CDC) estimates that in the US about two million people acquire serious infections with
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resistant bacteria, and that probably about 23,000 patients die each year as a direct consequence
of these infections. Gram-positive bacteria account for a large proportion of these infections
[1], and staphylococci and enterococci are the predominant species associated with these hos-
pital-acquired infections [2].
One of the major problems involves enterococci, mainly Enterococcus faecium resistant to
vancomycin (VRE) and most of them belonging to the clonal complex 17 (CC17). These bacte-
ria cause bloodstream infections, urinary tract infections and foreign-body infections (e.g. cath-
eters, stents, CNS shunts, artificial heart valves etc.) [3] mostly in immunocompromised
patients. For the US it is estimated that about 66,000 enterococcal infections occur each year,
and about 20,000 of these are due to multiple-drug-resistant (i.e. VRE) with about 1,300 death
per year. High rates are also seen for Staphylococcus aureus infections that are resistant to
methicillin (MRSA), causing mostly pneumonia, skin-, wound-, bloodstream- and surgical site
infections [4]. About 80,000 S. aureus infections have been reported in the US per year with
about 12,000 deaths caused by bacteria resistant to oxacillin/methicillin [2].
Here we present a discovery platform to identify antibodies from healthy individuals that




All animal experiments were performed in compliance with the German animal protection law
(TierSchG). The animals were housed and handled in accordance with good animal practice as
defined by FELASA and the national animal welfare body GVSOLAS. The animal welfare com-
mittees of the University of Freiburg (Regierungspraesidium Freiburg Az 35/9185.81/G-12/070
and Az 35/9185.81/G-07/72) approved all animal experiments. The institutional review board
of the University of Freiburg approved the study protocol. Moribund animals or animals in dis-
tress from infection (paucity of movement, ruffeled fur, reduced feeding or drinking) were hu-
manely eutanized by CO2 asphyxation. Animals were watched closely during the course of the
experiment (i.e. at least every 4 hours).
Collection of blood from human subjects was approved by the Ethics Committee of the Uni-
versity of Friburg (approval 116/04). Written consent was obtained prior to collection of blood
from healthy donors.
Bacterial Strains and Plasmids
Bacterial strains and plasmids used in the present study are shown in Table 1. E. coli were
grown with agitation at 37°C in Luria broth (LB; Roth) or LB Agar, while gram-positive bacte-
ria (S. aureus, E. faecalis 12030 and E. faecium) were grown in Tryptic Soy Broth (TSB) or
Tryptic Soy Agar (TSA) at 37°C without agitation. Antibiotics (all purchased from Sigma) were
added as indicated.
Opsonophagocytic assay
Opsonophagocytic killing was assessed as described by Theilacker et al. [5] using 1.7% baby
rabbit serum (Cedarlane) as complement source, and rabbit sera raised against purified lipotei-
choic acid (LTA) from E. faecalis 12030 as positive control [6–8]. Bacteria were incubated
and grown to mid-exponential (OD650nm) phase. Equal volumes of bacterial suspension (2.5 x
107 per mL), leukocytes (2.5 x 107 per mL), complement source (1.7% final concentration), and
culture supernatant of immortalized and stimulated B-cell cultures or heat-inactivated immune
Monoclonal Antibodies against Nosocomial Pathogens
PLOS ONE | DOI:10.1371/journal.pone.0118405 February 23, 2015 2 / 15
rabbit serum (as control) were combined and incubated on a rotor rack at 37°C for 90 minutes.
After incubation, live bacteria were quantified by agar culture of serial dilutions. Percent killing
was calculated by comparing the colony counts at 90 min (t90) of a control not containing
PMNs (PMNneg) to the colony counts of a tube that contained all four components of the assay
using the following formula: {[(mean CFU PMNneg at t90)—(mean CFU at t90)]/(mean CFU
PMNneg at t90)}×100.
EBV immortalization and identification of opsonic B-cell clones
Blood (10 mL) was taken by venipuncture from healthy volunteers and B-cells were isolated
and immortalized as described by Tosato et al. [9]. Immortalized cells were cultured in tissue
culture plates for 6 days and then stimulated by 40 μg/ml TNP-LPS (Biosearch Technologies),
10 U/mL hIl-1 (BD) and 100 U/ml hIl-2 (BD). The supernatant of each well was collected and
used in an opsonophagocytic killing assay (OPA) against E. faecalis 12030 to identify the well
resulting in the highest killing. B-cells from this well were distributed into a new tissue culture
plate. Supernatants were again tested by OPA and the cells of the well leading to the highest
killing were distributed into a new plate. After 4 rounds, B-cells in the wells with the strongest
response were lyzed and mRNA and cDNA was prepared.
Amplification of variable domains
Immortalized B-cells were cultured after the final round of selection for about 8 weeks until suffi-
cient numbers for RNA preparations were obtained. RNA was extracted from about 5 × 106 im-
mortalized cells using the RNeasy kit (QIAGEN) according to the manufacturer's instructions.
A 500 ng volume of total RNA was reverse-transcribed using the Omniscript kit (QIAGEN)
and 1 μl volume of the cDNA product was used as a template for PCRs. Primers for the am-
plification of the variable regions are listed in Table 2. Each reaction consisted of 50 μl PCR
Mix (HotStart Taq DNA Polymerase, QIAGEN), 100 pmol of each primer [10], and 1 μl
cDNA template. For PCR amplification 35 cycles were used with the following protocol: 95°C
for 30 s initially followed by cycles of 95°C for 30 s, 58°C for 30 s, and 68°C for 45 s, with a
final extension at 70°C for 10 min. PCR products were cloned into the TOPO cloning vector
Table 1. Bacterial strains, Antibodies and Plasmids.
Species Description Reference
E. coli Top 10 Competent cells Invitrogen
E. faecalis 12030 Clinical Isolate [33,34]
E. faecium 1162 [35]
S. aureus LAC CA-MRSA USA400 [10]
Antibodies
α-LTA rabbit serum raised against purified LTA from E. faecalis 12030 [7]
NRS normal rabbit serum (Cedarlane Labs
mouse α-LTA mAb IBT BIOSERVICES, Gaithersburg MD
VH4E, VH8 this study
S. aureus Newman USA300 [25]
plasmids Antibiotic resistance
TOPO 2.1 Cloning vector Ampicillin; Kanamycin Invitrogen
TCAE6.7 Eukaryotic expression vector containing human IgG1 and lambda domain Ampicillin; Neomycin [10]
doi:10.1371/journal.pone.0118405.t001
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2.1 (Invitrogen) and sequenced. The resultant sequences were compared against known germ
line sequences using IgBLAST (http://www.ncbi.nlm.nih.gov/igblast).
Cloning of variable domains into eukaryotic expression vector TCAE6.7
The TCAE6.7 vector containing the human lambda and IgG1 constant region was used as pre-
viously described [11,12]. Heavy (H) chain V-region genes from the four constructs were di-
gested with SalI and NheI restriction enzymes (NEB) and ligated into TCAE6.7 cut with the
same enzymes. The ligation reaction mixture was transformed into competent E. coli TOP10
cells (Invitrogen) and plasmids were purified using a plasmid Miniprep kit (QIAGEN). The
vector was sequenced to confirm the correct sequence. For light (L) chains, variable domains of
the light chain cloned into the TOPO cloning vector 2.1 were digested with BglII and AvrII re-
striction enzymes (NEB) and ligated with the TCAE6.7 vector already containing the matching
H chain variable region and cut with the same enzymes. Plasmids were transformed into E. coli
TOP10 cells (Invitrogen), individual colonies were isolated, plasmids were obtained, and the in-
serted DNA was sequenced to ensure that the correct L chain V-region was cloned into the eu-
karyotic expression vector. Since IgG1 has been reported to be superior to IgG3 in
complement-mediated killing of bacteria [13], we used IgG1 constant domains.
Transfection of CHO cells and expression of the recombinant antibody
molecules
Two constructs containing the different H chains (VH4E and VH8, see Table 3) combined
with the L chain were created and were transfected separately into Chinese Hamster Ovary
(CHO) DHFR−/− cells by using Lipofectamine 2000 (Invitrogen) according to the




















For the heavy chain primers the Sal I site is underlined and for the heavy constant primer the Nhe I site is underlined.
doi:10.1371/journal.pone.0118405.t002
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manufacturer's instructions. Stably transfected cells were selected using medium without nu-
cleotides (Biochrom). Culture supernatants of the transfected CHO cells were harvested daily
for 8 days. Supernatants containing monoclonal antibodies were pooled, precipitated with
ammonium sulfate (35% w/v), washed and dialyzed against phosphate-buffered saline (PBS)
(Biochrom) using Slide-A-Lyzer dialysis cassettes (MWCO 10; Thermo Scientific). Monoclonal
antibody (mAb) concentrations were determined by ELISA using the standards and the kit
from General Bioscience.
Opsonphagocytic inhibition
E. faecalis 12030 was either treated with 1M NaIO4 for 24 h in the dark or with Proteinase K
(1mg/ml, incubated in a shaking water bath at 54°C for 4 h). After 1M NaIO4 treatment, ethyl-
ene glycol was used to neutralize excess NaIO4. After Proteinase K treatment, extracts were in-
cubated for 1 h at 65° to inactivate Proteinase K and washed 3 times with saline. For inhibition
studies, either pre-treated bacterial cells or purified lipoteichoic acid was used as inhibitor.
VH4E (120 pg/mL) and VH8 (120 pg/mL) was diluted 1:50 and incubated for 60 min at 4°C
with an equal volume of a solution containing 20 or 100 μg cell wall extract (treated either with
NaIO4 or Proteinase K) from E. faecalis 12330 or 100 and 20 μg/mL lipoteichoic acid from S.
faecalis (E. faecalis) purchased from Sigma (St. Louis,Mo.). Subsequently, the respective anti-
body was used in the OPA as described above. Inhibition assays were performed at serum dilu-
tions yielding 50–80% killing of the inoculum without the addition of the inhibitor. The
percentage of inhibition of opsonophagocytic killing was compared to controls without inhibi-
tor [7].
Measurement of lipoteichoic acid specific IgG titers in monoclonal
antibody preparations
The total IgG concentration was determined for each monoclonal antibody preparation, with
the Easy-Titer Human IgG Assay kit (Thermo Scientific) according to the manufacturer’s in-
structions. Specific IgG titers against lipoteichoic acid were measured by ELISA as described
previously [14]. In brief, Nunc-immuno Maxisorp MicroWell 96 well plates were coated with
0.125 μg LTA from S. aureus purchased from Sigma (St. Louis, Mo.) in 0.2M carbonate-bicar-
bonate coating buffer. Plates were incubated overnight at 4°C, washed three times after incuba-
tion with PBS containing 0.05% Tween 20, and blocked with 3% bovine serum albumin
(Applichem GmbH) in PBS at 37°C for 2 hours. Rabbit sera were plated in twofold serial dilu-
tions and incubated 1 hour at 37°C, using three and four fold dilutions of each monoclonal an-
tibody preparation. Alkaline-phosphatase-conjugated anti-human IgG produced in goat
(Sigma) diluted 1:1,000 was used as secondary antibody and p-nitrophenyl phosphate (Sigma)
was used as substrate (1mg/mL in 0.1M glycine, 1mMMgCl2, 1mM ZnCl2, pH 10.4). After
60min of incubation at room temperature, the absorbance was measured at 405nm on a Tecan
Table 3. Sequences of heavy and light chain of the 4 antibodies isolated after the 4th round of selection.
Top V gene match Top D gene match Top J gene match Chain type Stop codon V-J frame Productive
IGHV1–69*06 IGHD3–9*01 IGHJ2*01 VH no in-frame yes
IGHV1–2*02 IGHD1–7*01 IGHJ6*04 VH no in-frame yes
IGLV1–51*01 — IGV1*01 VL no in-frame yes
Sequences have been analyzed with IgBlast.
doi:10.1371/journal.pone.0118405.t003
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Infinite 200 PRO (Tecan Group Ltd.). Each experiment was performed twice at different time-
points, and wells were measured in triplicate. The IgG titers were calculated as follows: for each
sample, a plot of OD value against the antibody dilution [Log10(antibody dilution)] was used to
calculate the dilution of monoclonal antibody giving an absorbance of 1 at 405nm after 60min
of incubation. The value extrapolated from the standard curve was calculated to generate the
final titer [15,16].
Mouse sepsis model
The protective efficacy of the monoclonal antibodies was tested against E. faecium and S. aure-
us LAC in a mouse bacteremia model as described previously [6]. Eight female BALB/c mice
6–8 weeks old (Charles River Laboratories Germany GmbH) were infected by i.v. injection of
E. faecium (1.8 x 108 cfu) or S. aureus (5.0 x 107 cfu) via the tail vein. Antibodies were given
48 h and 24 h prior to bacterial challenge i.p. in 200 μl saline. Mice were sacrificed 48 h (LAC)
and 24 h (E. faecium) after infection and livers were aseptically removed, weighted and homog-
enized. Bacterial counts were enumerated by serial dilutions on TSA plates after overnight in-
cubation. Statistical significance was assessed by Mann-Whitney test [7].
Rat endocarditis model
Female Wistar rats (Charles River Laboratories Germany GmbH), weighing 200 to 300g were
used in a previously described rat endocarditis model [17]. Animals were anesthetized by i.m.
application of 5.75% ketamine and 0.2% xylazine. Nonbacterial thrombotic endocarditis was
caused by insertion of a small plastic catheter (polyethylene tubing; Intramedic PE 10) via the
right carotid artery. Inoculation of bacteria was done after 48 h via injection into the tail vein.
Rats were challenged with E. faecalis 12030 (1.25 x 105 cfu per animal) and 4 animals received
the monoclonal antibody VH4E while 4 received normal rabbit serum (NRS). Animals were
sacrificed on postoperative day 6 and the correct placement of the catheter was confirmed in
6 rats (3 of each group). Two rats with incorrect catheter placement were excluded from the
final analysis. Endocarditis was assessed and graded macroscopically, and valve vegetations
were removed, weighted and homogenized. The primary evaluation criterion was the bacterial
count in the vegetation (cfu per gram and per ml, respectively). The mean and standard devia-
tion was calculated for each group.
Protection Studies
Bacterial strains S. aureusNewman and LAC (USA 300) were grown overnight in TSB. Cells
were harvested by centrifugation (4000 r.p.m., 30min, 4°C), washed and diluted to the correct
concentration in 0,9% NaCl to obtain a bacterial inoculum of 2x109 cfu/mL (inoculum stocks
are stored at -80°C). Eight female Balb-C mice 5–6 weeks old (Charles River Laboratories Ger-
many GmbH) were passively immunized by intraperitoneal injection of 200μL of either mono-
clonal antibody VH8 (diluted 1:50 in 0.9%NaCl corresponding to 4 ug/kg) or normal rabbit
serum (NRS) 24 hours before challenge. Mice were infected by intraperitoneal injection of
200μL of the bacterial inoculum (S. aureusNewman). The amount of bacteria in the inoculum
was verified by serial dilution and plating. Infected animals were monitored for morbidity or
recovery over a period of 72 hours. For the protection studies comparing VH8 and the mouse
anti-lipoteichoic monoclonal antibody, six female Balb-C mice 5–6 weeks old (Charles River
Laboratories Germany GmbH) were passively immunized by intraperitoneal injection of
200μL of the monoclonal antibodies 24 hours before bacterial challenge with S. aureus LAC.
Monoclonal antibody VH8 was adjusted to a final concentration of 12 ng/mL, while mouse
anti-lipoteichoic monoclonal antibody (IBT BIOSERVICES) was applied at 3000 ng/mL or
Monoclonal Antibodies against Nosocomial Pathogens
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12 ng/mL in 0.9% NaCl. Normal rabbit serum (NRS) and rabbit polyclonal anti-lipoteichoic
acid serum [7] were used as negative and positive controls, respectively. Mice were infected by
intraperitoneal injection of 200μL of bacterial inoculum. Infected animals were monitored for
morbidity or recovery over a period of 24 hours.
Statistical Analysis
All statistical testing was done using GraphPad PRISM with ANOVA and Dunnett, or Tukey
post tests as indicated. Two-group comparisons were done by unpaired t-test.
Results
A pre-screen of a donor pool by opsonophagocytic assay (OPA) was used to identify the donor
with the highest titers of opsonic antibodies against E. faecalis 12030. Healthy donor 2 showed
the highest opsonic killing (82%) using 1:100 serum (Fig. 1).
B-cells of donor 2 were immortalized using EBV, spread into tissue culture plates, and undi-
luted supernatants were tested by opsonophagocytic assay against E. faecalis 12030. The well
with the highest opsonic killing was selected, and B-cells in the respective well were removed,
cultured, and subsequently seeded into a new tissue-culture plate. After the 4th round, the con-
tent of the well with the highest titer was used to prepare mRNA and cDNA, and sequencing
revealed the presence of one light chain variable domain, and 2 different heavy chain variable
domains (see Table 3). After cloning of these heavy-light chain pairs into TCAE and transfec-
tion of these constructs into CHO cells, the recombinant monoclonal antibodies from the su-
pernatants were used to study the target of the monoclonal antibodies.
An opsonophagocytic Inhibition Assay (OPIA) was performed with mAbs VH4E and VH8
showing the highest killing against the tested strains to determine their bacterial target. Cell
wall extracts of E. faecalis 12030 were treated with Proteinase K or NaIO4 to assess if a polysac-
charide or a protein antigen is the target of the mAbs. Opsonic activity of VH4E and VH8 was
not inhibited when absorbing bacteria were treated with NaIO4, but was inhibited when
Fig 1. Opsonic killing of sera from healthy human volunteers.Opsonophagocytic killing against E.
faecalis 12030 was assessed in sera at a dilution of 1:100. Statistical analysis was done by ANOVA with
Dunnett post test. * p<0.05, ** p<0.01, *** p<0.001. Error bars represent standard error of the mean.
doi:10.1371/journal.pone.0118405.g001
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bacteria were treated with proteinase, indicating that a polysaccharide is the target of the mAbs
(Fig. 2A).
The binding affinity of the monoclonal antibodies was tested in an ELISA to assess whether
VH8 is directed against LTA, a carbohydrate-containg surface-exposed antigen. Binding of
VH4E and VH8 against staphylococcal LTA was compared to a mouse anti-lipoteichoic mono-
clonal antibody from S. aureus, known to be directed against LTA. Affinity of VH8 and VH4E
against LTA was clearly higher compared to the mouse anti-lipoteichoic monoclonal antibody
(Fig. 2B).
Using LTA as an inhibitor in an opsonophagocytic inhibition assay, we confirmed the speci-
ficity of VH8 and VH4E since concentrations of 100 μg/mL effectively inhibited killing by
67.75% and 98.75%, respectively (Fig. 2C).
In an opsonophagocytic assay, killing was tested against E. faecalis 12030 and S. aureus LAC
(CA-MRSA). Opsonic killing occurred in the presence of monoclonal antibodies in a dose-
Fig 2. Determination of the target of VH4E and VH8. (A) Opsonophagocytic Inhibition Assay after
absorbing mAbs with E. faecalis 12030 treated with Proteinase K or NaIO4 (B) Binding of VH4E and VH8 to
LTA is shown in an ELISA coating wells with S. aureus LTA (C) Osonophagocytic Inhibition Assay absorbing
monoclonal antibodies with LTA from S. aureus. (A) Killing of VH4E and VH8 against E. faecalis 12030 is
about 65% (first white or grey column) and killing is completely abolished when bacteria are treated with
proteinase K before absorption. Opsonic activity of VH4E and VH8 is not inhibited when mAbs are absorbed
with E. faecalis treated with NaIO4 indicating that a polysaccharide is the target of the mAbs. (B) Binding of
VH8 and the mouse anti-lipoteichoic monoclonal antibody to LTA was tested in an ELISA. As coating antigen
LTA from S. aureuswas used and serum dilutions are indicated in the X axis. Each point represents the
average of two measurements. (C) An Opsonophagytosis assay after absorbing monoclonal antibodies with
purified LTA confirmed the results of the ELISA. Opsonophagocytic killing was compared to controls from
which leukocytes were obtained. Statistical analysis was done by ANOVA with Dunnett post test. * p<0.05,
** p<0.01, *** p<0.001. Error bars represent standard error of the mean.
doi:10.1371/journal.pone.0118405.g002
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dependent manner (79–88% at the highest concentration of 3ng/mL against both strains),
whereas the absence of the mAbs but presence of neutrophils and complement alone did not
reduce viable counts (Fig. 3). A lipoteichoic acid-specific serum (αLTA T5) was used as positive
control because we have shown previously that this serum is opsonic and protective against en-
terococcal strains [7].
Passive immunotherapy with monoclonal antibodies VH4E and VH8 was studied in a mouse
bacteremia model. In this model we could demonstrate that VH4E and VH8 promote clearance
of E. faecium E1162 and S. aureus LAC, whereas normal rabbit sera (NRS) did not protect from
bacterial infection. The number of bacteria recovered from the liver and kidney of mice infected
with both strains was significantly reduced compared to those not being treated with the mAbs
(Fig. 4A and 4B). A lipoteichoic acid-specific serum (αLTA T5) was used as positive control.
Comparing monoclonal antibody VH4E with normal rabbit serum (NRS) in a rat endocar-
ditis model, bacterial vegetations of VH4E-treated rats were significantly reduced (measured in
cfu per milliliter and in milligram vegetation), compared to those not being treated with VH4E
the day before bacterial challenge (Fig. 4C and 4D).
In a different animal model, S. aureusNewman was injected i.p. and mice received VH8
(4 μg/kg per mouse in 200 μl saline) 24 hours before bacterial challenge. At an inoculum of 2 x
109 per mouse, all mice receiving NRS died after 18 hours, while 3/8 (37.5%) of animals receiv-
ing the monoclonal antibody survived (S1 Fig.). To compare the efficacy of VH8 and the
mouse anti-lipoteichoic monoclonal antibody, we passively immunized mice with VH8, the
mouse anti-lipoteichoic monoclonal antibody, normal rabbit serum, and anti-LTA serum
24 hours before bacterial challenge with S. aureus LAC. As shown in Fig. 5, only 1/6 mice
(83%) receiving VH8 died during the observation period of 19.5 hours, while 4/6 mice (33%)
died when 3 mg/ml (a 250x higher concentration) of the mouse anti-lipoteichoic monoclonal
antibodywas given. In the control group treated with normal rabbit serum, all animals died and
when the mouse anti-lipoteichoic monoclonal antibody was given at the same concentration as
for VH8 (12 ng/mL), all mice died after 8.75 hours (S1 Table). In this experiment, an anti-LTA
Fig 3. Measurement of opsonophagocytic killing of monoclonal antibodies VH4E and VH8 and the mouse anti-lipoteichoic monoclonal antibody
against (A) MRSA strain LAC and (B) E. faecalis 12030. The opsonophagocytic assay was performed using baby rabbit serum as complement source and
rabbit sera raised against purified LTA from E. faecalis 12030. VH4E and VH8 show high opsonic killing against both strains in a dose dependent manner and
are clearly more efficient than the mouse anti-lipoteichoic monoclonal antibody, which showed modest killing against LAC at very high concentrations (i.e.
1,000x). Opsonophagocytic killing activity was compared to controls from which leukocytes were omitted. Statistical analysis was done by ANOVA with
Dunnett post test. * p<0.05, ** p<0.01, *** p<0.001. Error bars represent standard error of the mean.
doi:10.1371/journal.pone.0118405.g003
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serum that was raised against LTA form E. faecalis 12030 did also not protect animals (1/6
mice survived).
Discussion
Research and development of new antibiotics has declined dramatically or has been completely
abandoned by most large pharmaceutical companies, mostly because of reduced profit margins
Fig 4. Investigating efficacy of the monoclonal antibodies in two independent animal models. Amouse bacterial sepsis model was tested for the
MRSA strain LAC (A) and E. faecium (B). A rat endocarditis model was confirms the protection of VH4E (C and D). In the mouse bacteremia model E.
faecium (1.8 x 108 cfu) or S. aureus (5.0 x 107 cfu) was injected i.v. into the tail vein. Cfu in the liver and the kidney was assessed after 24h. Statistical analysis
was done by ANOVA with Tukey post test (a and b). * p<0.05, ** p<0.01, *** p<0.001. Error bars represent standard error of the mean. A rat endocarditis
model confirmed protection against E. faecalis 12030 by VH4E (at a total concentration of 10 pg). Inoculation of bacteria was done 48 h after catheter
placement via injection into the tail vein. Bacterial counts in the vegetations (cfu per mg vegetation) are shown in (C), and (D) shows the absolute weights of
explanted vegetation. Differences in mg per vegetations are significant (p< 0.05) and were tested by unparied t-test (c and d). * p<0.05, ** p<0.01, ***
p<0.001. Error bars represent standard error of the mean.
doi:10.1371/journal.pone.0118405.g004
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[18]. On the other hand, the more than 40-year history of clinical trials of anti-inflammatory
strategies for the treatment of sepsis was described as 'graveyard' for the pharmaceutical indus-
try, especially regarding Gram-negative bacteria [19]. Several reasons for this assessment have
been mentioned: a) unsuitable animal models, b) inhomogeneity of the patient population en-
rolled in clinical studies, c) definition of sepsis itself (which is complicated because of the differ-
ent underlying conditions and dynamic time courses) [20]. However, the rapid rise of
multidrug-resistant pathogens, as demonstrated by the recent report from the Centers for Dis-
eases Control [2], illustrates the seriousness of the situation and classifies frighteningly many
pathogens (e.g. VRE, Pseudomonas aeruginosa, MRSA) as especially dangerous, since these are
often difficult or sometimes impossible to treat with currently available antibiotics [18].
In contrast to antibiotics, antibodies can be given prophylactically and could protect pa-
tients between one and four weeks from hospital-acquired infections [21]. Application of a pre-
formed monoclonal antibody would protect patients immediately, while active immunization
requires often booster dosages because the host needs time to develop and produce its own pro-
tective antibodies [22,23]. The use of monoclonal antibodies (mAbs) instead of antibiotics
would be advantageous also because it enables prophylaxis of patients at particular risk, such as
patients in intensive care units, patients after organ or bone-marrow transplantation, patients
after implantation of foreign materials (e.g. artificial heart valves or artificial joints), or after
chemotherapy. Development of resistance or immune evasion is very unlikely if highly con-
served structures (such as capsules or other cell-wall carbohydrate antigens) are targeted [24].
For the development of mAbs it would be advantageous to choose variable domains that recog-
nize cross-reactive antigens to cover a broad spectrum of pathogens [10,25].
Here we describe two human monoclonal antibodies that bind polysaccharide structures of
different Gram-positive bacteria and these bacteria can be subsequently eliminated by anti-
body-mediated complement deposition and phagocytosis (opsonizing antibodies). The strong
opsonizing activity could be demonstrated against two different enterococcal and two different
staphylococcal strains, among these a multidrug-resistant S. aureus (MRSA) and an E. faecium.
Three different animal models showed that the administration of the monoclonal antibodies
protected against infection also in vivo. However, the proposed treatment and/or prophylaxis
Fig 5. Protection against S. aureus LAC infection with VH8 andmouse anti-lipoteichoic monoclonal antibody. A dose of 12ng/mL VH8, 3000ng/mL
mouse anti-lipoteichoic monoclonal antibody and 200 μl of Normal Rabbit Serum were given to animals 24 hours before bacterial challenge. Strain S. aureus
LAC was used at a challenge dose of 2x109 cfu/mouse (6 mice per group). Protection by different sera was observed for VH8 (5/6 mice survived) while the
mouse anti-lipoteichoic monoclonal antibody and the NRS groupdid not result in protection.
doi:10.1371/journal.pone.0118405.g005
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with a monoclonal antibody will probably complement rather than replace current treatment
regimens and may act synergistically with antibiotic therapy.
The selection process of the antibodies described was carried out based on functions (i.e.,
uptake and killing of pathogens by phagocytes) and not—as in most approaches—on affinity.
We used as starting material the variety of antibodies in healthy individuals under the assump-
tion that healthy people have preformed protective mechanisms that eliminate a variety of
common pathogens. These "natural antibodies" are produced by specific B-cells and are direct-
ed against common microbial patterns, which are often polyreactive against widespread bacte-
rial structures and may also target several pathogenic species. The method described shows a
"proof of principle" which can be extended to a number of relevant hospital pathogens.
Our results indicate that the antibodies presented here are directed against lipoteichoic acid,
an antigen present in most Gram-positive bacteria. We have shown previously that antibodies
against LTA can be opsonic, protective, and cross-reactive between different Gram-positive
species [7]. Reichmann et al. recently reported that LTA is not surface exposed in S. aureus
[26]. However, data from other groups [27–29] and from our previous work [7] suggest that
some LTA epitopes are exposed on the surface of gram-positive cocci. This may depend on the
thickness of the cell wall or capsule (which may be strain-specific) and also on the target of the
anti-LTA antibodies used.
In our experiments here, anti-LTA serum did not show significant reduction in colony
counts when mice were infected with S. aureus LAC. However, in our previous study we did
not test S. aureus LAC. The reason for the resistance of LAC against anti-LTA serum is unclear
at this point and will be explored further. Nonetheless, as shown in Fig. 4A, and in Fig. 5, our
monoclonal antibodies were effective against this strain.
A chimeric monoclonal antibody against LTA (pagibaximab) has been previously developed
and tested in vitro and in vivo [30–32] by Biosnyexus (Gaithersburg, MD). This antibody con-
sists of the variable domains of a mouse monoclonal antibody and the constant domains of a
human IgG. This antibody promoted phagocytosis of staphylococci and inhibited LTA-mediat-
ed cytokine induction in vitro. At concentrations of 500 μg/ml it improved survival of suckling
rats challenged with S. aureus and coagulase-negative staphylococci [31]. A randomized, dou-
ble-blind placebo-controlled phase 2 study was conducted including 88 high-risk neonates
with birth-weights between 700 and 1,300 g in 10 neonatal intensive care units (NICUs). The
antibody was well tolerated and no staphylococcal or other gram-positive sepsis occurred in
neonates treated with pagibaximab [32]. A phase 2b/3 trial "Safety and Efficacy of Pagibaximab
Injection in Very Low Birth Weight Neonates for Prevention of Staphylococcal Sepsis"
(NCT00646399) was started in 2009 and completed in 2011 including 1,579 neonates, 792 re-
ceiving 6 doses of pagibaximab (100 mg/kg) and 787 receiving placebo (i.e. PBS). No publica-
tion or official statement regarding the results of this study exist, but information available at
ClinicalTrials.gov indicate that 63/792 (7.9%) neonates died in the pagibaximab group while
only 53/787 (6.7%) of neonates in the control group died. Regarding the primary endpoint (i.e.
cases of staphylococcal sepsis within 35 study days) there were 85/792 (10.2%) cases in the
pagibaximab group versus 79/787 (10.0%) in the control group.
Our results differ in several aspects from the data on pagibaximab because the opsonic and
protective efficacy of our antibodies is significantly better: in opsonophagocytosis 500 μg/ml
pagibaximab [31] vs. 3 ng/ml VH4E and VH8; and in animal models 80 mg/kg pagibaximab
[31] vs. 4 μg/kg VH4E and VH8. A direct comparison of the parent pagibaximab mouse mono-
clonal antibody with our antibodies in the same experiment confirmed these differences re-
garding affinity, opsonic killing, and protective efficacy in a mouse peritonitis model. In
addition, our monoclonal antibodies are fully human compared to the chimeric antibody from
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Biosynexus, making an anaphylactic or human-anti-mouse-antibody (HAMA/HACA)
response unlikely.
The reason for observed difference between pagibaximab and our antibodies may be the
exact epitope recognized by the monoclonal antibodies on the relatively complex LTA mole-
cule. We have shown previously that efficient and cross-reactive antibodies are directed against
the conserved polyglycerol-phosphate chain of LTA [7]. Sera raised against this epitope are op-
sonic against S. aureus, S. epidermidis, and enterococci [7]. However, using the pagibaximab
monoclonal antibody, we did not see efficient killing against enterococci, indicating that this
antibody may be directed against a different epitope on the LTA molecule (e.g. the glycolipid
anchor, or one of the decorations of the polyglycerol-phosphate chain, such as alanine). While
the above-mentioned issues may explain the different efficacy of pagibaximab and our mono-
clonal antibodies, the results of the phase 2b/3 trial may not represent the clinical efficacy of
antibodies against LTA since neonates, and especially premature babies, do not represent a
good study cohort, because of their immature immune system and often false-negative blood
cultures because of the small volume usually drawn.
While the data presented here are promising, additional in vitro studies and better clinical
trials are needed to establish monoclonal antibodies against LTA as therapeutic and/or prophy-
lactic strategies against multiresistant gram-positive pathogens.
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